Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Louisville, Kentucky 40202


The purpose of this study is to evaluate the effectiveness of a two-dose regimen of Procrit prior to a major surgical oncology operation.


Inclusion Criteria: - Undergoing a major surgical oncology procedure as defined below: - Pancreatectomy - Hepatectomy - Esophagectomy - Gastrectomy - Retroperitoneal Sarcoma Resection - 18 years of age and older - Hemoglobin level of ≥ 10g/dL to < 13g/dL, within 10 days of enrollment - If female of child-bearing potential, negative pregnancy test within 14 days prior to surgery - If subject is a sexually active male or a sexually active female of child- bearing potential, subject agrees to use a medically accepted form of contraception from the time of enrollment to completion of all follow-up study visits - IRB-approved informed consent, signed by the subject or the subject's legally authorized representative ≥ 18 years of age Exclusion Criteria: - Pre-operative hemoglobin level ≥ 13g/dL or < 10g/dL - Uncontrolled hypertension (defined as a systolic pressure ≥ 160 and/or a diastolic pressure ≥ 110) - History of allergy to Procrit® - Known hypersensitivity to mammalian cell-derived products or human albumin - History of spontaneous venous thrombotic vascular events - Anemia due to factors other than cancer,(e.g. iron deficiency, B12 deficiency) - History of (within 12 months) deep venous thrombosis (DVT), pulmonary embolus (PE), or other venous thrombotic events. Prior superficial thrombophlebitis is not an exclusion criterion - History of (within 6 months) uncontrolled cardiac arrhythmias, cerebrovascular accident (CVA), transient ischemic attack (TIA), acute coronary syndrome (ACS), or other arterial thrombosis. ACS includes Unstable Angina, Q wave Myocardial Infarction (QwMI), and non-Q wave myocardial infarction (NQMI) - Currently receiving therapeutic or prophylactic anticoagulants for conditions other than planned surgery. The only exceptions are low dose aspirin (≤ 325 mg/day) or low dose anticoagulant to maintain patency of intravenous (IV) lines - Patient is a candidate for autologous blood transfusion



Primary Contact:

Principal Investigator
Robert Martin, MD
University of Louisville

Backup Contact:


Location Contact:

Louisville, Kentucky 40202
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.